Evidence map›Paper›PMID 24649323›Full record

ArticleMolecular and clinical oncology2014

Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma.

Zhanmeng Zhu, Zhe Chen, Chunlin Chen, Ziyi Yang, Weibo Xuan, Yahui Hou, Yunfei Zuo, Shuangyi Ren

Abstract read
In one paragraph

Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhanmeng ZhuDepartment of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023;
Zhe ChenDepartment of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023;
Chunlin ChenDepartment of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023;
Ziyi YangDepartment of Clinical Biochemistry, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Weibo XuanDepartment of Clinical Biochemistry, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Yahui HouDepartment of Clinical Biochemistry, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Yunfei ZuoDepartment of Clinical Biochemistry, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Shuangyi RenDepartment of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023;

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate tumor biomarker carbohydrate antigen 724 (CA724) in the serum of patients with carcinomas of the colon and rectum at various clinical stages. Serum was collected from 51 patients with colon carcinoma (CC) and 49 patients with rectal carcinoma (RC). CA724 levels were then measured in the different groups according to site, TNM classification, gender, age and metastastic status of the patients. The statistical significance of the differences between the groups was calculated by non-parametric statistics (Mann-Whitney and Kruskall-Wallis tests). We observed a close association between the serum CA724 levels and tumor migration in colorectal carcinoma (CRC) and opposite variation tendencies of CA724 in the evolution of CC and RC. In conclusion, we identified a close association between the serum levels of CA724 and tumor migration in CRC. The opposite variation tendencies of CA724 in the different evolution groups of CC and RC may reflect the differences between these two types of cancer. The evaluation of serum CA724 may be of monitoring and and predictive value and may also assist in the development of treatment strategies for CRC patients.

Indexed as

carbohydrate antigen 724colon carcinomarectal carcinomatumor markers

Identifiers

PMID24649323
PMCPMC3916083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.